en · de · es · fr · pt
bench-notes.peptides6155.com › Topic › Tesamorelin Identity And Structure — Explained

Tesamorelin Identity And Structure — Explained

By Editorial Desk · published 2026-05-08 · last reviewed 2026-06-09 · Topic

Everything below concerns Visceral adiposity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-06-09. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tesamorelin Identity And Structure

Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.

Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.

Background And Regulatory Development

Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.

Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.

Tesamorelin at a glance

PropertyValueNotes
Chemical classSynthetic peptideGHRH analog family
Residue count44 amino acidsMatches human GHRH(1-44) backbone
N-terminal grouptrans-3-hexenoylMain structural difference from native hormone
AppearanceWhite to off-white powderLyophilized solid form
Solubility classFreely soluble in waterPeptide character; less soluble in organic solvents

Further detail

== Career == Eke's clinical and research career focuses on the intersection of maternal fetal medicine and pharmacologic research. He serves as the protocol chair for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) 2041, a phase I/II clinical trial evaluating the pharmacokinetics and safety of glecaprevir/pibrentasvir initiated during pregnancy among women with hepatitis C, including women co-infected with HIV. He is also involved in longitudinal cohort studies examining cardiovascular and metabolic outcomes in pregnant and postpartum women. His global health work includes contributions to Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB), a tuberculosis research initiative that integrates detection, prevention, and treatment strategies to reduce the burden of TB in high-risk settings. His broader research interests include optimizing drug safety and dosing in pregnancy and lactation, particularly in contexts such as preterm birth, HIV, tuberculosis, sickle cell disease, hypertensive disorders of pregnancy, and opioid use in pregnancy.

In normal-phase TLC, the stationary phase is polar. Silica gel is very common in normal-phase TLC. More polar compounds in a sample mixture interact more strongly with the polar stationary phase. As a result, more-polar compounds move less (resulting in smaller RF) while less-polar compounds move higher up the plate (higher RF). A more-polar mobile phase dissolves polar compounds more. As such, all compounds on the TLC plate move higher up the plate in polar solvent mixtures. "Strong" solvents move compounds higher up the plate, whereas "weak" solvents move them less. If the stationary phase is non-polar, like C18-functionalized silica plates, it is called reverse-phase TLC. In this case, non-polar compounds move less and polar compounds move more. The solvent mixture will also be much more polar than in normal-phase TLC.

== Reaction similarity == Similarity between enzymatic reactions (EC) can be calculated by using bond changes, reaction centres or substructure metrics (EC-BLAST Archived 30 May 2019 at the Wayback Machine).

These isoenzymes include MM, MB, and BB, which all carry out the same function given different amino acid sequences. The functions of these isoenzymes are to convert creatine, using ATP, into phosphocreatine expelling ADP. Mini columns were filled with DEAE-Sephadex A-50 and further eluted with tris- buffer sodium chloride at various concentrations (each concentration was chosen advantageously to manipulate elution). Human tissue extract was inserted in columns for separation. All fractions were analyzed to see total CK activity and it was found that each source of CK isoenzymes had characteristic isoenzymes found within. Firstly, CK- MM was eluted, then CK-MB, followed by CK-BB. Therefore, the isoenzymes found in each sample could be used to identify the source, as they were tissue specific. Using the information from results, correlation could be made about the diagnosis of patients and the kind of CK isoenzymes found in most abundant activity. From the finding, about 35 out of 71 patients studied suffered from heart attack (myocardial infarction) also contained an abundant amount of the CK-MM and CK-MB isoenzymes. Findings further show that many other diagnosis including renal failure, cerebrovascular disease, and pulmonary disease were only found to have the CK-MM isoenzyme and no other isoenzyme. The results from this study indicate correlations between various diseases and the CK isoenzymes found which confirms previous test results using various techniques.

Sources: en.wikipedia.org

Related pages on this site

Background from the literature

== Structure == Theoretical calculations have predicted the existence of metastable O4 molecules with two different shapes: a "puckered" square like cyclobutane or S4, and a "pinwheel" with three oxygen atoms surrounding a central one in a trigonal planar formation similar to boron trifluoride or sulfur trioxide. It was previously pointed out that the "pinwheel" O4 molecule should be the natural continuation of the isoelectronic series BO3−3, CO2−3, NO−3, and analogous to SO3; that observation served as the basis for the mentioned theoretical calculations.

Graphene is chemically dormant, mechanically sturdy, and non-permeable to gas or liquid. So, carbon plays a major role for fabrication of nanomaterials with porous nature. Graphene membranes that are formed by graphene oxide molecules or chemically converted graphene that is adhered with 2D nano mediated arrays have the ability to efficiently separate molecules in a gas or in a liquid phase. Graphene-coated nanomembranes are said to be more applicable in water treatment due to its unique properties. Graphene membranes are obtained from vacuum filtration or coating of graphene oxide solution as Graphene oxide sheets. The graphene coated nanofiltration membrane showed a higher water flux range. The graphene embedded with carbon nanotubes to serve as nanofilters is more useful for dye rejection in water effluent, removal of salt ions, and also acts as antifouling agent. Graphene nanofilter membranes possess effective antifouling agent due to its strong bond between graphene sheets and proteins. Also, graphene oxide coated nanofilter membranes helps in dechlorination of water. In addition to this, ultrathin nanofilter coated with graphene is the most potent filter that could be commercialized for water purification. Graphene oxide membranes can be used in various forms such as free, surface modified, and graphene cast in membranes in the range of micro, nano, or ultrafilters. Among which nanofilters is more efficient for water desalination due to its mechanical strength and physiochemical properties of the membrane.

=== Chemical === The chemistry of mendelevium is known largely in solution (as available quantities do not allow the creation of pure compounds), in which it can take on the +3 or +2 oxidation states. The +1 state has also been reported, but has not yet been confirmed. Before mendelevium's discovery, Seaborg and Katz predicted that it should be predominantly trivalent in aqueous solution and hence should behave similarly to other tripositive lanthanides and actinides. After the synthesis of mendelevium in 1955, these predictions were confirmed, first in the observation at its discovery that it eluted just after fermium in the trivalent actinide elution sequence from a cation-exchange column of resin, and later the 1967 observation that mendelevium could form insoluble hydroxides and fluorides that coprecipitated with trivalent lanthanide salts. Cation-exchange and solvent extraction studies led to the conclusion that mendelevium was a trivalent actinide with an ionic radius somewhat smaller than that of the previous actinide, fermium. Mendelevium can form coordination complexes with 1,2-cyclohexanedinitrilotetraacetic acid (DCTA). In reducing conditions, mendelevium(III) can be easily reduced to mendelevium(II), which is stable in aqueous solution. The standard reduction potential of the E°(Md3+→Md2+) couple was variously estimated in 1967 as −0.10 V or −0.20 V: later 2013 experiments established the value as −0.16±0.05 V. In comparison, E°(Md3+→Md0) should be around −1.74 V, and E°(Md2+→Md0) should be around −2.5 V.

Thus, PCI has been hypothesized to have a protective role: if acrosomal enzymes were released prematurely, or if the spermatozoa was degenerated within the male reproductive tract, the high concentrations of PCI would inhibit acrosin from inflicting proteolytic damage on nearby tissues.

The more electropositive atoms tend to instead lose electrons, creating a "sea" of electrons engulfing cations. The outer orbitals of one atom overlap to share electrons with all its neighbours, creating a giant structure of molecular orbitals extending over all the atoms. This negatively charged "sea" pulls on all the ions and keeps them together in a metallic bond. Elements forming such bonds are often called metals; those which do not are often called nonmetals. Some elements can form multiple simple substances with different structures: these are called allotropes. For example, diamond and graphite are two allotropes of carbon. The metallicity of an element can be predicted from electronic properties. When atomic orbitals overlap during metallic or covalent bonding, they create both bonding and antibonding molecular orbitals of equal capacity, with the antibonding orbitals of higher energy. Net bonding character occurs when there are more electrons in the bonding orbitals than there are in the antibonding orbitals. Metallic bonding is thus possible when the number of electrons delocalized by each atom is less than twice the number of orbitals contributing to the overlap. This is the situation for elements in groups 1 through 13; they also have too few valence electrons to form giant covalent structures where all atoms take equivalent positions, and so almost all of them metallise. The exceptions are hydrogen and boron, which have too high an ionisation energy.

Sources: en.wikipedia.org

Frequently asked questions

Is tesamorelin the same as growth hormone?

No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.

What does the trans-3-hexenoyl group do?

It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.

How long is the peptide chain?

The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.

What is tesamorelin made of?

It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.

Network